RxElite, Inc.
RXEI · OTC
12/31/2007 | 9/30/2006 | 9/30/2005 | 9/30/2004 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.00 |
| FCF Yield | -34,811.16% | 817.67% | -449.30% | 0.00% |
| EV / EBITDA | 0.58 | -0.27 | -0.14 | 0.00 |
| Quality | ||||
| ROIC | 84.12% | 39.52% | 0.00% | 0.00% |
| Gross Margin | 5.12% | 63.06% | 53.49% | 100.00% |
| Cash Conversion Ratio | 0.78 | 0.76 | -0.37 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 42.75% | 12.11% | 988,602.86% | 941,591.54% |
| Free Cash Flow Growth | -25,487.88% | 290.53% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.58 | -0.32 | 0.10 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 44.83 | 85.52 | 0.00 |
| Cash Conversion Cycle | 349.19 | 53.66 | 14.80 | 0.00 |